Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 14/20 | 0.43 |
| ▸ | CCND1 | P24385 | 13/20 | 0.43 |
| ▸ | CDK4 | P11802 | 7/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.43 |
| ▸ | CCND2 | P30279 | 3/20 | 0.41 |
| ▸ | CCND3 | P30281 | 3/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.32 |
| ▸ | CDK6 | Q00534 | 6/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL28575123 | 0.84 | NUAK1 (0.43) | CDK2CCND1CDK4CCNA2FGFR1 | |
| Methane SCHEMBL28462333 | 0.80 | CCNE1 (0.31) | CDK2CCND1CCNE1CDK6 | |
| Methane SCHEMBL4826066 | 0.80 | CCND1 (0.49) | CDK2CCND1CDK4CCNA2CCND2 | |
| Methane SCHEMBL28475491 | 0.79 | CCNE1 (0.31) | CDK2CCND1CCNE1CDK6 | |
| Methane SCHEMBL5900452 | 0.79 | CCNE1 (0.33) | CDK2CCND1CDK4CCNE1CDK6 | |
| Methane SCHEMBL4833118 | 0.79 | CCND1 (0.41) | CDK2CCND1CDK4CCNA2CCND2 | |
| Methane SCHEMBL5900460 | 0.79 | CDK4 (0.34) | CDK2CCND1CDK4CCNA2CCND2 | |
| Methane SCHEMBL28467115 | 0.79 | KCNH2 (0.33) | — | |
| Methane SCHEMBL4832996 | 0.78 | CDK4 (0.40) | CDK2CCND1CDK4CCNA2CCND2 | |
| Methane SCHEMBL5900481 | 0.77 | CCND1 (0.33) | CDK2CCND1CDK4CCNA2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456168-B2 | 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones | WARNER-LAMBERT COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070179118-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO [2,3 D]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY | 2007-08-02 | — | — | US | disclosed |
| US-7208489-B2 | Inhibitors of cyclin-dependent kinases 4 (cdk4); treating proliferative disorders such as cancer; salt of 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one for example | WARNER-LAMBERT COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1718645-A1 | 2-(PYRIDIN-3-YLAMINO)-PYRIDO 2,3-D PYRIMIDIN-7-ONES | Warner-Lambert Company LLC (US) | 2006-11-08 | — | — | EP | disclosed |
| EP-1470124-B1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | WARNER LAMBERT CO (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005082903-A1 | 2-(PYRIDIN-3-YLAMINO)-PYRIDO[2,3-D]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-09 | — | — | WO | disclosed |
| US-6936612-B2 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | WARNER-LAMBERT COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| US-20050182078-A1 | 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones | WARNER-LAMBERT COMPANY, LLC | 2005-08-18 | — | — | US | disclosed |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | WARNER-LAMBERT COMPANY | 2005-06-23 | — | — | US | disclosed |
| EP-1470124-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | Warner-Lambert Company LLC (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | BARVIAN MARK (US) | 2003-08-07 | — | — | US | disclosed |
| WO-2003062236-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | CDK4, CDK2, CDK1 | CDK2 2/4885CCND1 27/4885CDK4 1/4885 |
| US-20070179118-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO [2,3 D]PYRIMIDIN-7-ONES | CDK4, CDK2, CDKL4 | CDK2 2/4885CCND1 35/4885CDK4 1/4885 |
| US-20050182078-A1 | 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones | CDK2, CDK4, CDK1 | CDK2 1/4885CCND1 18/4885CDK4 2/4885 |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | CDK4, CDK2, CDK3 | CDK2 2/4885CCND1 34/4885CDK4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.